Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SLNO 
Soleno Therapeutics Inc (SLNO)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: SLNO (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $113.54
1 Year Target Price $113.54
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 215.96% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.79B USD | Price to earnings Ratio - | 1Y Target Price 113.54 |
Price to earnings Ratio - | 1Y Target Price 113.54 | ||
Volume (30-day avg) 8 | Beta -3.15 | 52 Weeks Range 41.50 - 90.32 | Updated Date 12/14/2025 |
52 Weeks Range 41.50 - 90.32 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -79.5% | Operating Margin (TTM) 34.41% |
Management Effectiveness
Return on Assets (TTM) -11.75% | Return on Equity (TTM) -20.66% |
Valuation
Trailing PE - | Forward PE 10.73 | Enterprise Value 2346650300 | Price to Sales(TTM) 28.3 |
Enterprise Value 2346650300 | Price to Sales(TTM) 28.3 | ||
Enterprise Value to Revenue 23.78 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 53710025 | Shares Floating 52979032 |
Shares Outstanding 53710025 | Shares Floating 52979032 | ||
Percent Insiders 1.84 | Percent Institutions 125.17 |
About Soleno Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-11-13 | Chairman, President, CEO & COO Dr. Anish Bhatnagar M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://soleno.life |
Full time employees 152 | Website https://soleno.life | ||
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.